Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Bill & Melinda Gates Foundation has approved a three-year grant that will lead to an expansion of the pharmacometric research group within MORU’s Department of Clinical Pharmacology.

Group photo of the Pharmacology team, with Joel Tarning

Head of Pharmacology Joel Tarning will be principal investigator for the grant, Model-based drug development platforms for antimalarials, which will be based at MORU in Bangkok, Thailand.

Malaria is still the most important parasitic disease of humans, killing almost 2,000 people each day, mainly young children under the age of five in tropical areas. The increasing prevalence of artemisinin-resistant falciparum malaria in Southeast Asia is now threatening our ability to control and eliminate malaria in the region and elsewhere and jeopardizing aspirations to eliminate malaria. ACT partner drug resistance is following so there is an urgent need now for novel, safe and effective antimalarial combination treatments with different mechanism of actions. However, drug development is slow and costly and in need of optimization to accelerate the delivery of novel antimalarial drugs and combinations in the market.

The overall goal of the proposed research, which will be done at MORU Pharmacology, is to develop a novel model-based platform for antimalarial drug development and optimize the use of existing antimalarial drugs. This could accelerate the development of new antimalarial drugs substantially, reduce costs and de-risk the process of bringing new antimalarial drug combinations to clinical care.

For more information, kindly contact John Bleho

Similar stories

Antimalarial chemoprophylaxis for forest goers could help accelerate malaria elimination in Cambodia

Giving people antimalarials during and after visiting the forest reduced their risk of contracting malaria 6-fold, and could be the missing piece towards eliminating malaria in Asia-Pacific and South America, say Mahidol and Oxford University researchers in a study published in The Lancet Infectious Diseases.

Four CTMGH researchers awarded full professorships

We are delighted to announce that four of our researchers have been awarded the title of Professor, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine, University of Oxford.

INTERBIO-21st study findings could help predict infants at risk of obesity

Fetal abdomen growth and the mother’s blood fat metabolites very early in pregnancy influence a child’s weight, body fat, vision and neurodevelopment at 2 years of age

Using mathematical modelling to fight malaria

Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.

MORU hepatitis work focusses on preventing mother-to-child transmission, high-at-risk populations, and remote communities

MORU Tropical Health Network researchers in Southeast Asia study various aspects of hepatitis B and C, infections that can lead to chronic liver diseases, and complications like liver cancer or cirrhosis. Researchers at MOCRU work on treatment for hepatitis C, a frequent opportunistic infection in HIV patients. MORU’s Clinical Pharmacology conducts two trials on possible treatments of hepatitis C. Hepatitis B is frequently transmitted from mother to child at birth, and SMRU researchers study mothers’ knowledge and behaviour, as well as prevention.

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.